Greater Carboxy-Methyl-Lysine Is Associated With Increased Fracture Risk in Type 2 Diabetes.
ADVANCED GLYCATION END-PRODUCTS
BIOMARKER
CARBOXY-METHYL-LYSINE
DIABETES
FRACTURE
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
20
09
2021
received:
17
05
2021
accepted:
02
10
2021
pubmed:
26
11
2021
medline:
15
3
2022
entrez:
25
11
2021
Statut:
ppublish
Résumé
Accumulation of advanced glycation end-products (AGE) in bone alters collagen structure and function. Fluorescent AGEs are associated with fractures but less is known regarding non-fluorescent AGEs. We examined associations of carboxy-methyl-lysine (CML), with incident clinical and prevalent vertebral fractures by type 2 diabetes (T2D) status, in the Health, Aging, and Body Composition cohort of older adults. Incident clinical fractures and baseline vertebral fractures were assessed. Cox regression was used to analyze the associations between serum CML and clinical fracture incidence, and logistic regression for vertebral fracture prevalence. At baseline, mean ± standard deviation (SD) age was 73.7 ± 2.8 and 73.6 ± 2.9 years in T2D (n = 712) and non-diabetes (n = 2332), respectively. Baseline CML levels were higher in T2D than non-diabetes (893 ± 332 versus 771 ± 270 ng/mL, p < 0.0001). In multivariate models, greater CML was associated with higher risk of incident clinical fracture in T2D (hazard ratio [HR] 1.49; 95% confidence interval [CI], 1.24-1.79 per 1-SD increase in log CML) but not in non-diabetes (HR 1.03; 95% CI, 0.94-1.13; p for interaction = 0.001). This association was independent of bone mineral density (BMD), glycated hemoglobin (hemoglobin A1c), weight, weight loss, smoking, cystatin-C, and medication use. CML was not significantly associated with the odds of prevalent vertebral fractures in either group. In conclusion, higher CML levels are associated with increased risk of incident clinical fractures in T2D, independent of BMD. These results implicate CML in the pathogenesis of bone fragility in diabetes. © 2021 American Society for Bone and Mineral Research (ASBMR).
Identifiants
pubmed: 34820902
doi: 10.1002/jbmr.4466
pmc: PMC8828668
mid: NIHMS1752021
doi:
Substances chimiques
Lysine
K3Z4F929H6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
265-272Subventions
Organisme : NIA NIH HHS
ID : R01 AG027012
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG017482
Pays : United States
Organisme : NIA NIH HHS
ID : R56-AG-02-0618
Pays : United States
Organisme : NIA NIH HHS
ID : N01-AG-6-2103
Pays : United States
Organisme : NINR NIH HHS
ID : R01 NR012459
Pays : United States
Organisme : NIA NIH HHS
ID : R01-AG-02-7012
Pays : United States
Organisme : NIA NIH HHS
ID : R56 AG020618
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG028050
Pays : United States
Organisme : NIA NIH HHS
ID : N01-AG-6-2106
Pays : United States
Organisme : NIA NIH HHS
ID : R01-AG17482
Pays : United States
Organisme : NIA NIH HHS
ID : N01-AG-6-2101
Pays : United States
Organisme : NIA NIH HHS
ID : R01-AG028050
Pays : United States
Organisme : NINR NIH HHS
ID : R01-NR012459
Pays : United States
Informations de copyright
© 2021 American Society for Bone and Mineral Research (ASBMR).
Références
J Bone Miner Res. 2020 Dec;35(12):2415-2422
pubmed: 32777114
Clin Chem Lab Med. 2005;43(5):503-11
pubmed: 15899672
JBMR Plus. 2021 Oct 19;5(11):e10548
pubmed: 34761150
Diabetes Care. 2013 Jun;36(6):1619-28
pubmed: 23315602
Osteoporos Int. 2013 Sep;24(9):2441-7
pubmed: 23471564
Bone. 2018 May;110:128-133
pubmed: 29408699
Sci Rep. 2020 Dec 16;10(1):22090
pubmed: 33328494
Circulation. 2002 Feb 19;105(7):816-22
pubmed: 11854121
Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1199-208
pubmed: 24723555
J Bone Miner Res. 2017 May;32(5):1072-1081
pubmed: 27982478
Int J Biochem Cell Biol. 2004 May;36(5):840-8
pubmed: 15006636
J Clin Endocrinol Metab. 2016 Jun;101(6):2502-10
pubmed: 27115060
Horm Metab Res. 2016 Nov;48(11):771-778
pubmed: 27728926
J Bone Miner Res. 2020 Dec;35(12):2363-2371
pubmed: 32717111
Diabetes Care. 2001 Jul;24(7):1198-203
pubmed: 11423502
Osteoporos Int. 2021 Dec;32(12):2543-2553
pubmed: 34333678
JAMA. 2011 Jun 1;305(21):2184-92
pubmed: 21632482
Kidney Int. 2004 Sep;66(3):1099-106
pubmed: 15327404
Osteoporos Int. 2014 Jul;25(7):1969-73
pubmed: 24718377
J Clin Endocrinol Metab. 2006 Sep;91(9):3349-54
pubmed: 16608888
Eur J Epidemiol. 1994 Aug;10(4):405-11
pubmed: 7843344
J Bone Miner Res. 2012 Feb;27(2):301-8
pubmed: 22052532
Bone. 2020 Aug;137:115457
pubmed: 32480023
J Gerontol A Biol Sci Med Sci. 2010 Sep;65(9):963-75
pubmed: 20478906
Diabetologia. 2004 Aug;47(8):1376-9
pubmed: 15258735
Diabetologia. 2005 Jul;48(7):1292-9
pubmed: 15909154
J Biol Chem. 2007 Feb 23;282(8):5691-703
pubmed: 17142454
J Clin Endocrinol Metab. 2018 Nov 1;103(11):4224-4231
pubmed: 30137355
J Bone Miner Res. 2018 Jan;33(1):63-69
pubmed: 28861910
J Bone Miner Res. 2013 Feb;28(2):313-24
pubmed: 22991256
Cardiovasc Res. 2004 Sep 1;63(4):582-92
pubmed: 15306213
PLoS One. 2012;7(4):e35047
pubmed: 22514706
Int J Biol Macromol. 2009 Jan 1;44(1):51-6
pubmed: 18984004
Bone. 2016 Jan;82:28-34
pubmed: 26211989
Bone. 2020 Nov;140:115556
pubmed: 32730921
Osteoporos Int. 2005 Dec;16(12):1683-90
pubmed: 15933802
Endocr J. 2004 Dec;51(6):537-44
pubmed: 15644571
J Clin Endocrinol Metab. 2008 Mar;93(3):1013-9
pubmed: 18160470
J Diabetes Res. 2019 Nov 25;2019:6757428
pubmed: 31886284
Diabetes Care. 2013 May;36(5):1153-8
pubmed: 23248194
Ann N Y Acad Sci. 2000 May;904:462-73
pubmed: 10865790
J Orthop Res. 2011 Apr;29(4):481-8
pubmed: 20957742
J Bone Miner Res. 2017 May;32(5):1062-1071
pubmed: 27943408
J Bone Miner Res. 2015 Jul;30(7):1338-46
pubmed: 25598134
Biomolecules. 2015 Mar 16;5(1):194-222
pubmed: 25786107
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2271-e2289
pubmed: 33475711
J Bone Miner Metab. 2008;26(1):93-100
pubmed: 18095070
J Bone Miner Res. 2011 Nov;26(11):2778-84
pubmed: 21773990
Osteoporos Int. 2006;17(7):1065-77
pubmed: 16758143
Arch Intern Med. 2007 Jan 22;167(2):133-9
pubmed: 17242313
Eur J Epidemiol. 2012 May;27(5):319-32
pubmed: 22451239
Osteoporos Int. 2010 Feb;21(2):243-50
pubmed: 19421701
J Bone Miner Res. 2019 Jul;34(7):1191-1206
pubmed: 30866111
J Bone Miner Res. 2003 Apr;18(4):784-90
pubmed: 12674340
J Bone Miner Res. 2005 Sep;20(9):1647-58
pubmed: 16059636
J Hypertens. 2015 Apr;33(4):797-803; discussion 803
pubmed: 25915884
J Clin Endocrinol Metab. 2009 Jul;94(7):2380-6
pubmed: 19383780
Calcif Tissue Int. 2008 Nov;83(5):324-31
pubmed: 18946627
Bone. 2018 Sep;114:32-39
pubmed: 29857063
Osteoporos Int. 2010 Feb;21(2):195-214
pubmed: 19760059
J Appl Physiol (1985). 2007 Dec;103(6):2068-76
pubmed: 17901242
J Bone Miner Res. 2014;29(5):1061-6
pubmed: 24877243